Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Toronto

$182,322.00

Degradable Cardiac Patch with Immuno-modulatory function

EF 2018-19

Résumé
Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012,*CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing*the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks*represent the main cause of CVD-related deaths, resulting in irreversible heart muscle*damage due to the limited regenerative capacity of the heart. This can ultimately lead to endstage*heart failure, which is currently treated using heart transplantation and ventricular assist*devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and*their lack of long-term suitability for all patient types are significant limitations of these*standard treatments. Tissue engineering and the development of cardiac tissue has become*a promising method for the repair and replacement of damaged myocardium and a means of*preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of*Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the*University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital*network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been*shown to modulate the early immune response upon implantation, will be combined with*cardiac cells, which will be derived from adipose stem cells, in order to develop a functional*and vascularized cardiac patch. The properties, performance and survival of the resulting*engineered patch will studied for their in vivo benefit.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
508415-2017
Name nom
Santerre, Paul
Department département
Dentistry, Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
182322
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Degradable Cardiac Patch with Immuno-modulatory function
Keyword
NSERC
Application summary
Cardiovascular disease (CVD) is the leading cause of death in the world. Specifically, in 2012,*CVD was responsible for ~17.5 million deaths globally and 62,000 deaths in Canada, costing*the Canadian economy more than $21.2 billion. Myocardial infarction or heart attacks*represent the main cause of CVD-related deaths, resulting in irreversible heart muscle*damage due to the limited regenerative capacity of the heart. This can ultimately lead to endstage*heart failure, which is currently treated using heart transplantation and ventricular assist*devices (VADs). However, a shortage of donor organs as well as the high cost of VADs and*their lack of long-term suitability for all patient types are significant limitations of these*standard treatments. Tissue engineering and the development of cardiac tissue has become*a promising method for the repair and replacement of damaged myocardium and a means of*preventing end-stage heart failure. In this project, and utilizing the biomaterial expertise of*Santerre lab and the cardiovascular biology expertise of the Bendeck lab (both at the*University of Toronto) and clinical expertise of the Dr. Epelman lab at the University Hospital*network, a novel degradable polyurethane scaffold, using a biomaterial platform that has been*shown to modulate the early immune response upon implantation, will be combined with*cardiac cells, which will be derived from adipose stem cells, in order to develop a functional*and vascularized cardiac patch. The properties, performance and survival of the resulting*engineered patch will studied for their in vivo benefit.